Genmab A/S GMAB 深 滬
交易中 09-20 11:46:08 美东时间
25.6079
-0.872
-3.29%
華盛通- 最 高25.935
- 今 開25.92
- 成交量 19.56万股
- 最 低 25.605
- 昨 收 26.48
- 總市值 162.63亿
- 52周最高 36.71
- 市盈率 靜 26.73
- 換手率 0.03%
- 52周最低 24.53
- 委 比 4.49%
- 總股本 6.35亿
- 歷史最高 49.07
- 量 比 1.36
- 振 幅 1.25%
- 歷史最低 16.24
- 每 手 1
- 風險率 2.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Genmab Announces Strategic Financial Updates
Genmab (GMAB) has released an update. Genmab A/S, the Copenhagen-based biotech ...
09-12 04:17
Morgan Stanley Maintains Equal-Weight on Genmab, Maintains $31 Price Target
Morgan Stanley analyst Vikram Purohit maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and maintains $31 price target.
09-11 23:36
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
In today's rapidly changing and highly competitive business world, it is impera...
09-11 23:00
Maintaining Hold on Genmab: Awaiting Detailed Data on Rina-S’s Market Potential
Leerink Partners analyst Jonathan Chang has reiterated their neutral stance on ...
09-11 14:07
AbbVie declares $1.55 dividend
AbbVie (NYSE:ABBV) declared $1.55/share quarterly dividend, in line with previous. Forward yield 3.19% Payable Nov. 15; for shareholders of record Oct. 15; ex-div Oct. 15. See ABBV Dividend Scorecard,...
09-06 22:16
Genmab’s Hold Rating: Balancing Stability and Uncertainty
Vikram Purohit, an analyst from Morgan Stanley, maintained the Hold rating on G...
09-04 15:16
Genmab’s TEPKINLY Gains EU Approval for Lymphoma
Genmab (GMAB) has released an update. Genmab A/S has announced the European Com...
08-21 23:17
艾伯维(ABBV.US)潜在重磅双特异性抗体疗法再获欧盟批准
8月20日，艾伯维(ABBV.US)和Genmab(GMAB.US)共同宣布，欧盟委员会已经批准Tepkinly(epcoritamab)扩展适应症，用于治疗复发或难治性(R/R)滤泡性淋巴瘤(FL)成人患者。
08-20 21:12
Decoding 10 Analyst Evaluations For Genmab
10 analysts have expressed a variety of opinions on Genmab (NASDAQ:GMAB) over t...
08-20 20:00
JP Morgan Downgrades Genmab to Neutral
JP Morgan analyst James Gordon downgrades Genmab (NASDAQ:GMAB) from Overweight to Neutral.
08-20 18:36
